Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,342 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05435248RecruitingPhase 1/Phase 2
Study drug for advanced lung cancer with a specific EGFR change
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
Guangzhou, GuangdongAges 18 years+ - NCT07671417RecruitingEarly Phase 1
Imaging study for advanced clear cell kidney cancer
This early-phase study uses a special imaging agent called RYZ512 to see how it works in people with advanced clear cell kidney cancer that has spread. Participants will receive RYZ512 and have scans; you may qualify if you can pause certain medications temporarily.
Saint Leonards, New South WalesAges 18 years+ - NCT07671092RecruitingEarly Phase 1
Imaging study for advanced cancers
This trial is testing a new imaging method to see if it can help find cancer that has spread in people with certain advanced cancers like bladder cancer, breast cancer, or lung cancer.
St Leonards, New South WalesAges 18 years+ - NCT06674343RecruitingPhase 3
Furmonertinib for advanced lung cancer with EGFR mutations
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05983523RecruitingPhase 1
Study of PEP07 for advanced solid tumors
This study tests a new pill called PEP07 for people with advanced or metastatic solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if PEP07 can help shrink or control the cancer.
TaichungAges 20 years+ - NCT07660211RecruitingPhase 1
Radioactive treatment for advanced prostate cancer
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06411600RecruitingPhase 2
Combination therapy for BRAF-mutated colorectal cancer
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
BarcelonaAges 18 years+ - NCT06532812RecruitingPhase 1/Phase 2
TIL therapy plus immunotherapy for advanced breast cancer
This trial tests a personalized therapy using your own immune cells (TILs) combined with immunotherapy to fight advanced breast cancer that has not responded to other treatments. It may help if you have a tumor that can be biopsied and you are generally healthy enough for the procedures.
Beijing, Beijing MunicipalityAges 16–90 - NCT07641049RecruitingPhase 1
CAR-NK Cell Therapy for Advanced Prostate Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
Shenzhen, GuangdongAges 18 years+ - NCT07640295RecruitingPhase 1/Phase 2
New drug plus chemo for advanced pancreatic cancer with KRAS mutation
This study tests a new drug combined with chemotherapy for people with pancreatic cancer that has spread and has a KRAS gene mutation. It may help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07642375Recruiting
Digital Tools to Manage Sarcoma Treatment Side Effects
This study tests whether a digital app or online tool can help you better manage symptoms and side effects from your sarcoma treatment. Researchers want to see if tracking your symptoms online improves how you feel during cancer care.
AthensAges 18 years+ - NCT07645690RecruitingEarly Phase 1
CD70 CAR-T Cell Therapy for Advanced Kidney Cancer
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
BeijingAges 18–75 - NCT07635147Recruiting
Decision Support Tool for Advanced Breast Cancer
This study tests a digital tool designed to help patients with advanced (stage IV) breast cancer make treatment decisions. The tool may help you understand your options and feel more confident discussing them with your doctor.
Brooklyn, New YorkAges 18 years+ - NCT07636148Recruiting
Registry of minimally invasive cancer treatment with advanced imaging
This study collects information from patients undergoing minimally invasive procedures to treat solid tumors (cancers) using advanced CT imaging guidance. Researchers want to understand how well this imaging technique helps doctors perform these procedures safely and effectively.
Lyon, Auvergne-Rhône-AlpesAges 18 years+ - NCT07627698RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Melanoma
This trial tests engineered immune cells (CAR-NK cells) designed to target two markers found on melanoma cells. The goal is to help patients with melanoma that has spread or cannot be surgically removed and has not responded to or is unsuitable for standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07623174Recruiting
Fruquintinib for Advanced Colorectal Cancer in Poland
This study follows adults in Poland who are receiving fruquintinib, a targeted cancer medicine, for advanced colorectal cancer that has spread. You would be enrolled if your doctor is already planning to give you fruquintinib as a later-line treatment after other therapies have stopped working.
Poznan, Greater Poland VoivodeshipAges 18 years+ - NCT06685276RecruitingPhase 2
Combination therapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
BeijingAges 18–75 - NCT07619599RecruitingPhase 1
PET Scan to Track Lung Cancer Treatment Response
This study uses a special PET imaging scan to help doctors see how well pembrolizumab (an immunotherapy drug) is working against advanced non-small cell lung cancer. You'll receive the scan along with your regular pembrolizumab treatment and possible radiation therapy to help measure treatment response.
Duarte, CaliforniaAges 18 years+ - NCT07617610Recruiting
Understanding Treatment Resistance in BRAF-Mutated Colorectal Cancer
This study looks at why some people with a specific type of colorectal cancer (BRAF V600E-mutated) stop responding to targeted drugs over time. Researchers will take small tissue samples before and during your treatment with anti-EGFR antibody and BRAF inhibitor to understand resistance and help improve future treatments.
AarauAges 18 years+ - NCT07612891RecruitingPhase 1/Phase 2
Testing INV-6452 for advanced breast cancer and solid tumors
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07617805RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Head and Neck Cancer
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07607054RecruitingPhase 1
EMB-15 for advanced solid tumors without standard treatment
This is a first-time-in-humans study testing a new drug called EMB-15 for patients with advanced cancers that have spread or cannot be surgically removed. The drug targets proteins called ALPP/ALPG, which may help your immune system fight cancer cells.
Guangzhou, GuangdongAges 18 years+ - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
Dothan, AlabamaAges 18 years+ - NCT07610720RecruitingPhase 2
Dalpiciclib With Anti-HER2 and Hormone Therapy for Advanced Breast Cancer
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
Guangdong, GUANGZHOUAges 18–75
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,342 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.